pubmed-article:10779159 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0032636 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0020410 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0017337 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C1422036 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C0870432 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C1511636 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C1705417 | lld:lifeskim |
pubmed-article:10779159 | lifeskim:mentions | umls-concept:C1555465 | lld:lifeskim |
pubmed-article:10779159 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:10779159 | pubmed:dateCreated | 2000-6-30 | lld:pubmed |
pubmed-article:10779159 | pubmed:abstractText | An important goal in cancer gene therapy is the development of novel targeted cytotoxic genes. The observation that transfection of a GaLV envelope glycoprotein lacking an R peptide into human cells results in considerable cell-cell fusion and subsequent cell death prompted us to explore the potential for using this fusogenic membrane glycoprotein (FMG) as a targeted cytotoxic gene. As proof of principle, we therefore displayed epidermal growth factor (EGF) on the N terminus of GaLV envelope glycoproteins both with and without an R peptide (GaLV R+ and GaLV R-). Transfection of the GaLVR+ envelope expression plasmids did not cause cell-cell fusion. The GaLV R+ envelopes were incorporated into retroviral vectors whose infectivity was investigated on EGF receptor-positive and -negative cells. The vector incorporating an N-terminally unmodified envelope was able to infect all human cell lines tested. Infectivity of the vector incorporating an envelope on which EGF was displayed was restricted on EGF receptor-positive cells (but not on EGF receptor-negative cells) and could be restored by protease cleavage of the displayed domain or competition with exogenous ligand. The cell-cell fusion capacity of the GaLV R- envelope glycoproteins (N-terminally unmodified and with N-terminal display of both EGF and insulin-like growth factor I [IGF-I]) was investigated by plasmid DNA transfection. While the N-terminally unmodified GaLV R- fused all human cell types tested, fusogenicity of GaLV R- on which EGF or IGF-I was displayed was considerably restricted on receptor-positive cells. "Reciprocal" competition experiments showed that fusogenicity could be restored by competition only with the relevant exogenous ligand. Thus the specificity of cell-cell fusion by a hyperfusogenic GaLV envelope glycoprotein can be regulated by N-terminal display of growth factor ligands. There is therefore significant potential for further development of the targeting of the cell-killing capability of this fusogenic viral glycoprotein by using strategies similar to those we have developed for the targeting of retroviral vectors. | lld:pubmed |
pubmed-article:10779159 | pubmed:language | eng | lld:pubmed |
pubmed-article:10779159 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10779159 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:10779159 | pubmed:month | Apr | lld:pubmed |
pubmed-article:10779159 | pubmed:issn | 1043-0342 | lld:pubmed |
pubmed-article:10779159 | pubmed:author | pubmed-author:RussellS JSJ | lld:pubmed |
pubmed-article:10779159 | pubmed:author | pubmed-author:CossetF LFL | lld:pubmed |
pubmed-article:10779159 | pubmed:author | pubmed-author:ChadwickM PMP | lld:pubmed |
pubmed-article:10779159 | pubmed:author | pubmed-author:FieldingA KAK | lld:pubmed |
pubmed-article:10779159 | pubmed:author | pubmed-author:Chapel-Fernan... | lld:pubmed |
pubmed-article:10779159 | pubmed:author | pubmed-author:BulloughF JFJ | lld:pubmed |
pubmed-article:10779159 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:10779159 | pubmed:day | 10 | lld:pubmed |
pubmed-article:10779159 | pubmed:volume | 11 | lld:pubmed |
pubmed-article:10779159 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:10779159 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:10779159 | pubmed:pagination | 817-26 | lld:pubmed |
pubmed-article:10779159 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:meshHeading | pubmed-meshheading:10779159... | lld:pubmed |
pubmed-article:10779159 | pubmed:year | 2000 | lld:pubmed |
pubmed-article:10779159 | pubmed:articleTitle | A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. | lld:pubmed |
pubmed-article:10779159 | pubmed:affiliation | Hematology and Molecular Medicine, Mayo Clinic, Rochester, MN 55902, USA. | lld:pubmed |
pubmed-article:10779159 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:10779159 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10779159 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10779159 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10779159 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10779159 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10779159 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10779159 | lld:pubmed |